Polyethylene Glycol-conjugated L-asparaginase Versus Native L-asparaginase in Combination With Standard Agents for Children With Acute Lymphoblastic Leukemia in Second Bone Marrow Relapse: A Children's Oncology Group Study (POG 8866)

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Journal of pediatric hematology/oncology

• Publication date

  2011-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/MPH.0b013e31822d4d4ePMID 22042277PMCID PMC3557823
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• General principles of chemotherapy.

  2010cited by this paper
• Allergic Reactions to E. coli L-Asparaginase Do Not Affect Outcome in Childhood B-precursor Acute Lymphoblastic Leukemia: A Children's Oncology Group Study

  2007cited by this paper
• Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia.

  2000cited by this paper
• Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a Pediatric Oncology Group Study.

  2000cited by this paper
• The three asparaginases. Comparative pharmacology and optimal use in childhood leukemia.

  1999cited by this paper
• The Three Asparaginases

  1999cited by this paper
• Pharmacokinetic dose adjustment of Erwinia asparaginase in protocol II of the paediatric ALL/NHL‐BFM treatment protocols

  1999cited by this paper
• Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study

  1999cited by this paper
• Use of L-asparaginase in childhood ALL.

  1998cited by this paper
• High-dose cytosine arabinoside and L-asparaginase in refractory acute lymphoblastic leukemia: the Children's Cancer Group experience.

  1998cited by this paper
• Consolidation therapy with antimetabolite-based therapy in standard-risk acute lymphocytic leukemia of childhood: a Pediatric Oncology Group Study.

  1998cited by this paper
• Toxicity, pharmacology and feasibility of administration of PEG-L-asparaginase as consolidation therapy in patients undergoing bone marrow transplantation for acute lymphoblastic leukemia

  1998cited by this paper
• Successful treatment of relapsed infant acute lymphoblastic leukemia with intensive antimetabolite-based chemotherapy.

  1997cited by this paper
• An open‐label, multicenter study of polyethylene glycol‐L‐asparaginase for the treatment of acute lymphoblastic leukemia

  1995cited by this paper
• Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber Cancer Institute/Children's Hospital Acute Lymphoblastic Leukemia Consortium Protocol 85-01.

  1994cited by this paper
• Comparative pharmacokinetic studies of three asparaginase preparations.

  1993cited by this paper
• Asparaginase revisited.

  1993cited by this paper
• Non-Hodgkin's lymphomas in elderly patients.

  1993cited by this paper
• Allergic reactions to Erwinia asparaginase in children with acute lymphoblastic leukemia who had previous allergic reactions to escherichia coli asparaginase

  1992cited by this paper
• Non-randomised study comparing toxicity of Escherichia coli and Erwinia asparaginase in children with leukaemia.

  1990cited by this paper
• More is better! Update of Dana-Farber Cancer Institute/Children's Hospital childhood acute lymphoblastic leukemia trials.

  1990cited by this paper
• Principles and Practice of Pediatric Oncology

  1989cited by this paper
• Reinduction therapy in 297 children with acute lymphoblastic leukemia in first bone marrow relapse: a Pediatric Oncology Group Study.

  1988cited by this paper
• Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia.

  1986influential reference
• Cancer therapy with chemically modified enzymes. I. Antitumor properties of polyethylene glycol-asparaginase conjugates.

  1984cited by this paper
• Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia.

  1983cited by this paper
• L-Asparaginase as a single agent in acute lymphocytic leukemia: survey of studies form Childrens Cancer Study Group.

  1981cited by this paper
• Improved treatment results in the management of single and multiple relapses of acute lymphoblastic leukemia

  1980cited by this paper
• Human pharmacology and toxicology of succinylated Acinetobacter glutaminase-asparaginase.

  1979cited by this paper
• Treatment of L5178Y tumor-bearing BDF1 mice with a nonimmunogenic L-glutaminase-L-asparaginase.

  1979cited by this paper
• Vincristine and prednisone vs vincristine, L-asparaginase, and prednisone for second remission induction of acute lymphocytic leukemia in children.

  1979cited by this paper
• Effective dose of L-asparaginase for induction of remission in previously treated children with acute lymphocytic leukemia: a report from Childrens Cancer Study Group.

  1979cited by this paper
• Evaluation of intramuscular versus intravenous administration of L-asparaginase in childhood leukemia.

  1979cited by this paper
• Improvement in the therapeutic, immunological, and clearance properties of Escherichia coli and Erwinia carotovora L-asparaginases by attachment of poly-DL-alanyl peptides.

  1979cited by this paper
• Comparison of anaphylactic reactions to asparaginase derived from Escherichia coli and from Erwinia culturs

  1976cited by this paper
• Therapy with Erwinia l‐asparaginase in children with acute leukemia after anaphylaxis to E. coli l‐asparaginase

  1974cited by this paper
• Toxicity of L‐asparaginase in children with advanced leukemia

  1972cited by this paper
• Erwinia carotovora asparaginase in patients with prior anaphylaxis to asparaginase from E. coli

  1972cited by this paper
• Treatment of adult leukemia with L-asparaginase (NSC-109229).

  1971cited by this paper
• Methotrexate therapy of Wegener's granulomatosis.

  1971cited by this paper
• L-asparaginase: clinical, biochemical, pharmacological, and immunological studies.

  1971cited by this paper
• Toxicity of E. coli L‐asparaginase in man

  1970cited by this paper
• E. coli L‐asparaginase in the treatment of leukemia and solid tumors in 131 children

  1970cited by this paper
• L-asparagine requirement and the effect of L-asparaginase on the normal and leukemic human bone marrow.

  1970cited by this paper
• L-asparaginase: therapeutic and toxic effects in patients with neoplastic disease.

  1969cited by this paper
• Two L-asparaginases from Escherichia coli B. Their separation, purification, and antitumor activity.

  1967cited by this paper
• Inhibition of leukemias in man by L-asparaginase.

  1967cited by this paper
• Toxic and antineoplastic effects of l‐asparaginase: Study of mice with lymphoma and normal monkeys and report on a child with leukemia

  1966cited by this paper
• The antitumor activity of Escherichia coli L-asparaginase.

  1966cited by this paper

• Current status and emerging frontiers in enzyme engineering: An industrial perspective

  2024cites this paper
• Exploring the therapeutic potential of biosynthetic enzymes in cancer treatment: Innovations and implications.

  2024cites this paper
• Enzyme Engineering Strategies for the Bioenhancement of l-Asparaginase Used as a Biopharmaceutical

  2023cites this paper
• l-Asparaginase as the gold standard in the treatment of acute lymphoblastic leukemia: a comprehensive review

  2023cites this paper
• Is PEGylation of Drugs Associated with Hypersensitivity Reactions? An Analysis of the Italian National Spontaneous Adverse Drug Reaction Reporting System

  2023cites this paper
• Clinical summary of pediatric acute lymphoblastic leukemia patients complicated with asparaginase-associated pancreatitis in SCCLG-ALL-2016 protocol

  2023cites this paper
• Pegylated Asparaginase‐Induced Liver Injury: A Case‐Based Review and Data From Pharmacovigilance

  2022cites this paper
• Asparaginase: How to Better Manage Toxicities in Adults

  2022cites this paper
• Cost-Utility Analysis of Pegaspargase for the Treatment of Acute Lymphoblastic Leukemia in Greece

  2022cites this paper
• Pegaspargase in Practice: Minimizing Toxicity, Maximizing Benefit

  2021cites this paper
• Clinical Utility of Pegaspargase in Children, Adolescents and Young Adult Patients with Acute Lymphoblastic Leukemia: A Review

  2021cites this paper
• Clinical Characteristics and Short-Term Outcomes of Children With Asparaginase-Associated Pancreatitis

  2021cites this paper
• BLCTT_A_245210 25..40

  2021cites this paper
• University of Birmingham Utilizing functionalized bromomaleimides for fluorogenic conjugation and PEGylation of enzymes

  2020cites this paper
• Excessive toxicities of pegylated asparaginase in pediatric acute lymphoblastic leukemia patients with high body surface area: A call for action

  2020cites this paper
• The Physiopathology of T- Cell Acute Lymphoblastic Leukemia: Focus on Molecular Aspects

  2020cites this paper
• Efficacy and safety of PEG-asparaginase versus E. coli L-asparaginase in Chinese children with acute lymphoblastic leukemia: a meta-analysis

  2020cites this paper
• Recombinant l‐ asparaginase production using Pichia pastoris ( MUT s strain): establishment of conditions for growth and induction phases

  2020cites this paper
• Strategies to Overcome Resistance Mechanisms in T-Cell Acute Lymphoblastic Leukemia

  2019cites this paper
• Amino Acid Metabolism in Hematologic Malignancies and the Era of Targeted Therapy.

  2019cites this paper
• PEG-asparaginase and native Escherichia coli L-asparaginase in acute lymphoblastic leukemia in children and adolescents: a systematic review

  2019cites this paper
• Pegaspargase: A Review in Acute Lymphoblastic Leukaemia

  2019influential citation
• Antibodies Predict Pegaspargase Allergic Reactions and Failure of Rechallenge.

  2019cites this paper
• Experience with generic pegylated L-asparaginase in children with acute lymphoblastic leukemia and monitoring of serum asparaginase activity

  2018cites this paper
• Prolonged first‐line PEG‐asparaginase treatment in pediatric acute lymphoblastic leukemia in the NOPHO ALL2008 protocol—Pharmacokinetics and antibody formation

  2017cites this paper
• Risk Factors for Asparaginase-associated Pancreatitis: A Systematic Review

  2017cites this paper
• Novel agents for the treatment of childhood leukemia: an update

  2017cites this paper
• Differentiating hypersensitivity versus infusion-related reactions in pediatric patients receiving intravenous asparaginase therapy for acute lymphoblastic leukemia

  2017cites this paper
• Management of adults with T-cell lymphoblastic leukemia.

  2017cites this paper
• Drug-induced amino acid deprivation as strategy for cancer therapy

  2017cites this paper
• PEG-asparaginase in BFM-90 regimen improves outcomes in adults with newly diagnosed lymphoblastic lymphoma

  2017cites this paper
• Oncogene-Driven Metabolic Alterations in Cancer

  2017cites this paper
• Cancer Biology and the Principles of Targeted Cancer Drug Discovery

  2017cites this paper
• Extraction of Anticancerous Enzymes from E.coli and a New Method to Study itsActivity

  2017cites this paper
• Novel agents for the treatment of childhood leukemia: an update

  2017cites this paper
• Allergic Reactions With Intravenous Compared With Intramuscular Pegaspargase in Children With High-risk Acute Lymphoblastic Leukemia: A Population-based Study From the Maritimes, Canada

  2016cites this paper
• Pegylated-asparaginase during induction therapy for adult acute lymphoblastic leukaemia: toxicity data from the UKALL14 trial

  2016cites this paper
• Allergic reactions associated with pegaspargase in adults

  2016cites this paper
• A phase 2 study of methotrexate, etoposide, dexamethasone, and pegaspargase chemotherapy for newly diagnosed, relapsed, or refractory extranodal natural killer/T‐cell lymphoma, nasal type: a multicenter trial in Northwest China

  2016cites this paper
• Impact of anti-PEG IgM antibodies on the pharmacokinetics of pegylated asparaginase preparations in mice.

  2016cites this paper
• Drug hypersensitivity in children: report from the pediatric task force of the EAACI Drug Allergy Interest Group

  2016cites this paper
• Final results of a single institution experience with a pediatric‐based regimen, the augmented Berlin–Frankfurt–Münster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper‐CVAD regimen

  2016cites this paper
• Clinical study of l‐asparaginase in the treatment of extranodal NK/T‐cell lymphoma, nasal type

  2016cites this paper
• Immunology of infusion reactions in the treatment of patients with acute lymphoblastic leukemia.

  2016cites this paper
• Asparaginase pharmacokinetics and implications of therapeutic drug monitoring

  2015cites this paper
• Allergic Reactions Associated with Intravenous Versus Intramuscular Pegaspargase: A Retrospective Chart Review

  2015cites this paper
• Augmented Berlin‐Frankfurt‐Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL)

  2014cites this paper
• Czynniki warunkujące aktywność terapeutyczną L-asparaginazy

  2014cites this paper
• Comparison of Allergic Reactions to Intravenous and Intramuscular Pegaspargase in Children with Acute Lymphoblastic Leukemia

  2014cites this paper
• How to manage asparaginase hypersensitivity in acute lymphoblastic leukemia.

  2014cites this paper
• Consideration of Glucocorticoids and Escherichia coli-derived L-asparaginase in the treatment of pediatric acute lymphoblastic leukemia.

  2013cites this paper
• Asparaginases: biochemical pharmacology and modes of drug resistance.

  2012cites this paper